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expanded	CAG	repeat	within	 the	huntingtin	 (HTT)	 gene.	The	Q140	and	HdhQ150	
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1  | INTRODUC TION
Huntington’s	 disease	 (HD)	 is	 an	 autosomal	 dominant,	 progressive,	














1999)	 develop	 HD‐related	 phenotypes	 with	 an	 early	 onset	 that	
progresses	 rapidly	and	 leads	 to	a	considerably	 shortened	 lifespan.	







created	 by	 replacing	 the	mouse	 (CAG)2CAA(CAG)4	 sequence	with	






respectively,	 injecting	 these	 into	 C57BL/6J	 blastocysts	 (Lin	 et	 al.,	
2001;	Menalled	et	al.,	2003)	and	backcrossing	to	C57BL/6J,	to	pro-
duce	mice	with	a	mixed	strain	background.




analysis	 of	 the	HdhQ150	mice	 using	 the	 same	 tests	 has	 not	 been	
performed,	however,	the	available	data	indicate	that	behavioral	phe-
notypes	present	much	later	(Brooks,	Higgs,	Jones,	&	Dunnett,	2012;	
Heng,	 Tallaksen‐Greene,	 Detloff,	 &	 Albin,	 2007;	 Lin	 et	 al.,	 2001;	
Woodman	 et	 al.,	 2007).	 These	 data	 suggest	 that	 sequence	 differ-








We	 reasoned	 that	 if	 differences	 in	 the	 onset	 of	 behavioral,	 neu-
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2  | MATERIAL S AND METHODS
2.1 | Animals
At	 UCLA,	 all	 procedures	 on	mice	were	 carried	 out	 in	 accordance	
with	 the	NIH	Guide	 for	 the	 Care	 and	 Use	 of	 Laboratory	 Animals	
(NIH	 Publications	 No.	 80‐23)	 revised	 1996,	 and	 approved	 by	 the	
UCLA	Institutional	Animal	Care	and	Use	Committee.	In	the	United	
Kingdom,	all	animal	care	and	procedures	were	performed	in	compli-
ance	with	United	Kingdom	Home	Office	 regulations	 (Animals	 and	
Scientific	Procedures	Act	1986)	and	were	approved	by	the	University	
Ethical	Review	Process	Committee.







































Therefore,	 the	 HdhQ150	 mice	 had	 significantly	 longer	 CAG	 repeat	







2.1.2 | zQ175 and zQ175DN knock‐in mice
The	 zQ175	 knock‐in	 line	 arose	 through	 a	 spontaneous	 expansion	 of	
the	CAG	repeat	 in	 line	Q140	(Heikkinen	et	al.,	2012;	Menalled	et	al.,	
2012)	 and	 both	 the	Q140	 and	 zQ175	 lines	 retained	 a	 neomycin	 re-
sistance	gene	cassette	 located	1.3	kb	upstream	of	 the	ATG.	 In	order	
to	test	whether	this	might	affect	the	expression	of	Htt,	or	the	level	of	
incomplete	splicing,	we	utilized	zQ175	mice,	from	the	CHDI	Foundation	
colony	 at	 the	Jackson	 Laboratories	 (Bar	Harbor,	Maine)	 in	which	 the	










2.2 | Cohorts of mice used for behavioral testing
The	numbers	of	animals	used	was	based	on	previous	experiments	




2.2.1 | Cohorts of mice used for the open field,  









Mut	=	mutant.	For open field:	Q140	WT	(n = 10; male n	=	3,	 female	
n	 =	7),	Q140	Mut	 (n = 9; male n	 =	4,	 female	n	 =	5),	HdhQ150	WT	
(n = 20; male n	 =	10,	 female	n	 =	10),	HdhQ150	Mut	 (n = 20; male 
n	=	12,	female	n	=	8).	For Y‐maze testing:	Q140	WT	(n = 7; male n	=	3,	
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female	n	=	4),	Q140	Mut	(n = 5; male n	=	2,	female	n	=	3),	HdhQ150	
WT	(n = 14; male n	=	7,	female	n	=	7),	HdhQ150	Mut	(n = 10; male 
n	=	6,	female	n	=	4).	For the pole task:	Q140	WT	(n = 10; male n	=	6,	
female	n	=	4),	Q140	Mut	(n = 9; male n	=	4,	female	n	=	5),	HdhQ150	







2.2.2 | Cohorts of mice used for the running wheel 


















2.3.1 | Open field (1, 4 and 6 months of age)
Behavior	in	an	open	field	apparatus	(Tru	Scan,	Colbourn,	Allentown	








2.3.2 | Spontaneous alternation in the Y‐maze 
(3 months of age)
The	Y‐maze	was	used	to	test	spatial	working	memory	(Magen	et	al.,	
2012).	The	apparatus	was	a	three‐arm	horizontal	maze	 in	which	the	










could	 not	 be	 seen	 by	 the	 animal	 during	 this	 time.	After	 7	min,	 the	

















2.3.4 | Running wheel (6–6.5 months of age)
Mice	were	placed	individually	in	cages	equipped	with	a	running	wheel	
(23	cm	diameter,	Mini	Mitter	Company	 Inc.,	Bend,	OR).	Each	wheel	













The	 antibodies	 that	 were	 used	 for	 immunohistochemistry,	 immu-
noprecipitation	 and	 western	 blotting	 are	 summarized	 in	 Table	 1.	 
     |  5FRANICH et Al.
3B5H10	 (RRID:AB_532270)	 is	 a	 monoclonal	 antibody	 that	 was	
raised	against	an	N‐terminal	171	amino	acid	fragment	of	HTT	with	




3B5H10	 recognize	 an	 expanded	 polyQ	 tract	 and	MW8	 acts	 as	 a	
neoepitope	antibody	on	western	blots	that	detects	the	AEEPLHRP	
peptide	at	the	C‐terminus	of	exon	1	HTT	Landles	et	al.	(2010).	These	





and	 12–13	months	 of	 age	were	 perfused	 transcardially	with	 0.01M	



















visualized	by	 incubation	 in	0.03%	3‐3′‐diaminobenzidine	 tetrahydro-
chloride	(Sigma,	St.	Louis,	MO)	and	0.0006%	H2O2	in	0.05	M	Tris	buffer,	
pH	7.6.	After	rinses	in	cold	Tris	buffer,	the	sections	were	dehydrated,	
defatted	 in	xylene,	and	mounted	with	Eukitt	 (Calibrated	 Instruments,	
Hawthorne,	 NY).	 Images	 of	 HTT	 staining	 were	 captured	 using	 an	
Olympus	microscope	connected	to	a	PC	with	SPOT	imaging	acquisition	
software.









(Stoelting	 Co.,	 Wood	 Dale,	 IL).	 Dissected	 tissue	 was	 snap‐fro-
zen	 in	 liquid	nitrogen	 and	 stored	 at	 −80º	C.	 Total	RNA	was	puri-
fied	 from	 fresh‐frozen	 brain	 tissue	 using	Qiagen	 RNeasy	mini	 kit	
(Qiagen)	according	to	the	manufacturers	recommendations.	During	
the	RNA	extraction	procedure,	on‐column	DNase	I	treatment	was	
performed	 to	 remove	 contaminating	 genomic	 DNA	 (RNase‐Free	
DNase	Set,	Qiagen).	RNA	was	stored	at	−80°C.	RNA	integrity	was	
confirmed	 using	 a	 BioAnalyzer	 (Agilent	 RNA	 6000	 Nano	 Assay,	
UCLA	Genotyping	and	Sequencing	Core).	For	cDNA	synthesis	with	
random	 hexamer	 primers,	 a	 High‐Capacity	 cDNA	 reverse	 tran-
scription	(RT)	kit	(Applied	Biosystems)	was	used.	cDNA	was	stored	
at	−20°C.	The	cDNA	was	 then	analyzed	by	quantitative	 real	 time	
PCR	 (qPCR)	using	 an	Applied	Biosystems	7900HT	Real	 time	PCR	
machine	(UCLA	Genotyping	and	Sequencing	Core).	PCR	reactions	




dopamine‐	 and	 cAMP‐regulated	 phosphoprotein	 32	 (Darpp32),	
Mm00454892_m1;	dopamine	receptor	D1	(Drd1a),	Mm01353211_
m1;	 dopamine	 receptor	 D2	 (Drd2),	 Mm00438545_m1;	 cannabi-
noid	 receptor	1(Cnr1),	Mm01212171_s1;	 preproenkephalin	 (Penk),	
Mm01212875_m1;	 high‐affinity	 glutamate	 transporter	 1	 (Glt1),	
Mm00441457_m1;	substance	P	receptor	(Tac1),	Mm00436892_m1.	
Identification	numbers	of	Applied	Biosystems	 inventoried	primer‐
probe	 set	 TaqMan	 assays	 of	 striatal	 and	 cortical	 reference	 genes	
were:	 ATP	 synthase,	H	 +	 transporting	mitochondrial	 F1	 complex,	
beta	 subunit	 (Atp5b),	 Mm00443967_g1;	 eukaryotic	 translation	
initiation	 factor	 4A2	 (Eif4a2),	 Mm00834357_g1;	 peptidylprolyl	
isomerase	A	(Ppia),	Mm02342429_g1.	For	each	gene,	RT	+	samples	
from	 each	 animal	 and	 no‐template	 controls	 samples	 were	 run	 in	
TA B L E  1  Summary	of	the	antibodies
Name Epitope Species Concentration Source
MW1 PolyQ Mouse	monoclonal WB	(1:1,000) CHDI	Foundation
MW8 AEEPLHRP Mouse	monoclonal WB	(1:1,000) CHDI	Foundation
IHC	(1:1,000)
3B5H10 PolyQ Mouse	monoclonal IP	2	µg Sigma	P1874
Abbreviations:	IHC,	immunohistochemistry;	IP,	immunoprecipitation;	WB,	western	blotting.
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2.8 | Analysis of Htt transcripts by quantitative real‐
time PCR
Fresh	 striatal,	 cortical,	 and	 cerebellar	 tissue	 was	 dissected	 from	
mice	at	2	months	of	age,	snap‐frozen	 in	 liquid	nitrogen	and	stored	
at	 −80ºC.	 Tissue	 was	 homogenized	 in	 Qiazol	 buffer	 (Qiagen)	 
before	total	RNA	isolation	using	the	QiaGen	RNeasy	mini	kit	(Qiagen)	
and	RNA	was	quantified	using	a	Nanodrop	1000.	RNA	was	reverse	
transcribed	 using	 MMLV‐RT	 (Invitrogen)	 and	 oligo‐dT	 primers	
(Invitrogen)	and	cDNA	was	stored	at	−20°C.	qPCR	was	performed	
using	 SsoFast	 Probes	 Supermix	 (Bio‐Rad)	 with	 a	 corresponding	
cycler	 program	 using	 a	 CFX	 96	 qPCR	 system	 (Bio‐Rad).	 Primer‐
probe	 set	 gene	 expression	 assays	 for	 the	Htt	 intron	 1	 sequences	








A	 critical	 value	 of	 p	 <	 0.05	 was	 used	 for	 all	 statistical	 analysis.	
Grubb’s	test	for	outliers	was	performed	on	data	from	each	treat-
ment	group	and	 if	 a	 significant	outlier	was	 identified	 in	a	group,	
it	 was	 removed	 before	 comparisons	 between	 groups	 were	 per-
formed.	 SigmaPlot	 v12	 (Systat)	 or	 SPSS	 (v22)	 was	 used	 for	 all	
statistical	 analysis	 using	 one‐way	 ANOVA,	 two‐way	 ANOVA,	
or	 repeated‐measures	 two‐way	 ANOVA,	 as	 appropriate,	 with	
Bonferroni	or	Fisher’s	 LSD	post	hoc	 tests,	 as	 indicated.	Planned	
comparison	 Student’s	 t	 tests	 were	 also	 used	 where	 indicated.	
Graphs	were	prepared	using	GraphPad	Prism.
3  | RESULTS
To	evaluate	whether	phenotypes	develop	at	different	 rates	 in	 the	
Q140	 and	HdhQ150	 KI	 mice,	 we	 began	 by	 standardizing	 the	 ge-






3.1 | Q140 homozygotes, but not HdhQ150 
homozygotes are impaired in behavioral tasks before 
6 months of age






[two‐way	 repeated	 measures	 ANOVA,	 F(genotype)3,106	 =	 6.419,	








3.1.2 | Spontaneous alternation in a Y‐maze
Spatial	working	memory	was	tested	by	spontaneous	alternation	in	a	
Y‐maze	in	3	month	old	mice	(Figure	1b).	Q140	mice	showed	a	reduced	
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3.1.4 | Performance in a running wheel




ANOVA:	 F(genotype)3,372	 =	 2.035,	 p	 =	 0.129,	 F(night)12,372	 =	 23.795,	





In	 summary,	 homozygous	Q140	have	decreased	 locomotion	 in	





3.2 | HTT immunostaining detects aggregates in the 
striatum earlier in Q140 than in HdhQ150 mice
The	choice	of	antibody	for	use	in	immunohistochemical	experiments	
to	 investigate	 the	 timing	 of	 HTT	 deposition	 in	 the	 brains	 of	 these	
two	 mouse	 models	 had	 to	 be	 considered	 carefully.	 The	 Q140	 and	
HdhQ150	mice	express	human	and	mouse	exon	1	HTT,	respectively,	


















animals	 (Figure	2e).	At	12–13	months	of	age,	 the	nuclear	 inclusions	
and	 neuropil	 aggregates	 were	 readily	 observed	 in	 both	 Q140	 and	
HdhQ150	striata	(Figure	2c,f),	and	the	Q140	mice	appeared	to	have	
smaller	nuclear	inclusions	and	a	greater	number	of	neuropil	aggregates.
3.3 | Homozygous Q140 and HdhQ150 mice have 
similar levels of transcriptional dysregulation in the 
striatum at 6.5 months of age





Q140	 and	HdhQ150	mice	 could	 be	 observed	 at	 the	 level	 of	 tran-
scriptional	changes,	we	measured	the	levels	of	selected	striatal	tran-
scripts	 by	 real	 time	 quantitative	 PCR	 (qPCR)	 in	male	 homozygous	
Q140	 and	HdhQ150	mice	 at	 6.5	months	 of	 age.	 Brains	 had	 been	
























The	expression	 levels	of	 the	 striatal	 genes:	dopamine	 receptor	
D2	(Drd2),	preproenkephalin	(Penk1),	Darpp32,	and	cannabinoid	re-
ceptor	1	(Cnr1)	mRNAs	were	decreased	in	both	Q140	and	HdhQ150	
mice	 (Figure	 3a,b).	 This	 is	 consistent	 with	 our	 previous	 data	 for	
4.5	month	old	homozygous	Q140	mice	on	a	mixed	strain	background	
(Hickey,	 Franich,	 Medvedeva,	 &	 Chesselet,	 2011).	 Therefore,	 the	
Q140	and	HdhQ150	mice	have	similar	decreases	 in	the	expression	








3.4 | The incomplete splicing of Htt is greater in the 











might	 underlie	 the	 differences	 in	 the	 onset	 of	HD‐related	 pheno-
types	in	these	mouse	models.
We	measured	 the	 level	 of	 intron	 1	 sequences,	 using	 a	 qPCR	
assay	 that	 amplified	 sequences	 located	 in	 the	 5′	 region	 of	 Htt 
intron	 1,	 before	 the	 first	 cryptic	 polyadenylation	 site.	 RNA	was	
prepared	from	striatum,	cortex,	and	cerebellum	from	2	month	old	




in	 the	 striatum,	 between	 1.5‐	 and	 2‐fold	 higher	 in	 the	 cortex,	
and	approximately	1.3‐fold	higher	 in	 the	cerebellum.	 Incomplete	




statistically	 significantly	decreased	 in	 the	 striatum	and	cortex	 in	
HdhQ150	mice,	and	there	was	a	trend	toward	a	reduction	 in	the	
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Q140	mice	in	both	of	these	brain	regions,	when	compared	to	their	
WT	littermates	(Figure	4b),
We	 used	 the	 3B5H10	 antibody	 to	 immunoprecipitate	 HTT	
from	the	brains	of	heterozygous	Q140	and	HdhQ150	mice	at	2	and	
12	months	of	age.	Heterozygous	mice	were	chosen	for	this	purpose	
because	 in	 homozygous	 mice,	 the	 difference	 in	 polyQ	 length	 on	
the	mutant	HTT	alleles	makes	 it	difficult	 to	 interpret	 the	patterns	
of	 N‐terminal	 fragments	 immunoprecipitated	 from	 their	 brains.	
The	 3B5H10	 antibody	 recognizes	 an	 expanded	 polyQ	 repeat	 and	
so	 does	 not	 immunoprecipitate	HTT	 from	WT	 tissues	 (Figure	 4c).	
In	 contrast,	 immunodetection	 with	MW1	 showed	 that	 full‐length	
HTT,	as	well	as	 the	characteristic	pattern	of	N‐terminal	 fragments	
(Landles	et	al.,	2010),	were	immunoprecipitated	from	both	Q140	and	
HdhQ150	brains.	Comparison	of	fragment	 intensities	 in	the	 immu-
noprecipitates	from	the	brains	of	both	mouse	models	at	2	months	
of	age,	did	not	demonstrate	any	obvious	differences	for	fragments	
F I G U R E  3  Expression	level	of	striatal	transcripts	in	homozygous	Q140	and	HdhQ150	mice	and	their	WT	littermates	at	6.5	months	
of	age.	Relative	levels	of	selected	striatal	transcripts	assessed	by	qPCR	in	6.5‐month–old‐male	(a)	homozygous	Q140	mice	(n	=	5–6)	
and	WT	littermates	(n	=	7–8)	and	(b)	homozygous	HdhQ150	mice	(n	=	8)	and	WT	littermates	(n	=	8).	One‐way	ANOVA	comparing	all	
four	genotypes	with	Fisher’s	LSD	post	hoc	tests,	mean	+	SEM: Drd2: F(genotype)3,25	=	3.990,	p = 0.019; Penk: F(genotype)3,25	=	5.917,	
p = 0.003; Darpp32: F(genotype)3,26	=	4.463,	p = 0.012; Cnr1: F(genotype)3,25	=	6.526,	p = 0.002; Drd1a: F(genotype)3,25	=	2.338,	
p	=	0.098;	Glt1: F(genotype)3,26	=	2.388,	p = 0.092; Tac1: F(genotype)3,26	=	0.519,	p	=	0.673.	#Planned	comparison	two‐tailed	Student’s	
t	tests.	Drd2	=	dopamine	receptor	D2,	Penk1	=	preproenkephalin,	Darpp32	=	dopamine‐	and	cAMP‐regulated	phosphoprotein	32,	
Cnr1	=	cannabinoid	receptor	1,	Glt1	=	glutamate	transporter,	Tac1	=	tachykinin	1	receptor	(Substance	P	receptor)
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running	at	~70	kDa	and	above.	However,	the	intensity	of	the	small-
est	fragment	that	had	migrated	to	the	bottom	of	the	gel	appeared	







mice	 (Figure	 4c).	 The	 exon	 1	HTT	 protein	was	 not	 present	 in	 the	
12	month	Q140	or	HdhQ150	lysates,	as	by	this	age	it	has	been	re-
cruited	into	aggregates.
3.5 | The presence of a neomycin cassette in the 
Q140 line is unlikely to influence the levels of 
incomplete splicing
In	 engineering	 the	Q140	mice	 to	 express	 a	 chimeric	Htt	 gene	with	
human	exon	1	and	an	expanded	CAG	repeat,	a	neomycin	resistance	
gene	remained	located	1.3	kb	5′	to	the	ATG.	Although	this	neo	gene	
was	 transcribed	 in	 the	 opposite	 direction	 to	Htt,	 it	 is	 possible	 that	
its’	 presence	might	 influence	 the	 level	 of	 incomplete	 splicing	 in	 the	
Q140	mice.	A	spontaneous	CAG	repeat	expansion	 in	 the	Q140	 line	
has	 led	 to	 the	 knock‐in	mouse	 line	 now	 dubbed	 zQ175	 (Heikkinen	 
et	al.,	2012;	Menalled	et	al.,	2012),	from	which	the	neomycin	cassette	



















old	 zQ175	mice,	with	 and	without	 the	 neomycin	 cassette.	The	 lev-
els	of	5′	 intron	1	sequence,	before	the	first	cryptic	polyA	site,	were	
measured	by	qPCR	in	the	striatum,	cortex,	and	cerebellum	(Figure	5a).	
There	 was	 no	 difference	 in	 the	 levels	 of	 these	 intronic	 sequences	 
between	the	zQ175	and	zQ175DN	mice	in	any	of	these	brain	regions.	
Therefore,	the	presence	of	the	neomycin	cassette	in	the	Q140	mice	











2012;	 Lin	 et	 al.,	 2001;	Menalled	 et	 al.,	 2003;	 Rising	 et	 al.,	 2011;	
Simmons	 et	 al.,	 2009;	 Woodman	 et	 al.,	 2007).	 To	 systematically	
evaluate	 these	 potential	 differences,	 we	 standardized	 the	 genetic	















and HdhQ150	knock‐in	 lines	 (Woodman	et	al.,	2007).	Within	neu-











Q140	 and	 HdhQ150	 mice,	 we	 performed	 immunohistochemistry	
with	MW8,	an	antibody	 for	which	 the	AEEPLHRP	epitope	 is	pres-
ent	in	both	mouse	and	human	HTT,	and	therefore,	in	both	of	these	
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mouse	 lines.	At	4.5	months	of	age,	 immunostaining	with	MW8	re-
vealed	a	prominent	neuronal	nuclear	staining	pattern	that	was	barely	








detected	 in	 the	HdhQ150	 line.	 It	would	 be	 necessary	 to	measure	

































taneous	CAG	 repeat	 expansion	 in	 the	Q140	 line	 (Menalled	et	 al.,	
2012),	and	zQ175	and	Q140	mice	carry	the	same	modifications	to	

























compared	 to	mouse	exon	1	 sequences.	Alternatively,	 splicing	 en-
hancers	that	are	located	in	the	5′	region	of	intron	1	might	have	been	
deleted	in	the	Q140	line.





and	 contains	 promoter	 sequences,	Htt	 exon	 1	 and	 some	 intron	 1	
sequences	 (Mangiarini	 et	 al.,	 1996).	 The	 transgene	 is	 transcribed	
from	the	human	promoter,	through	the	human	exonic	and	 intronic	










pathological	 phenotypes	 that	 we	 have	 assessed,	 may	 be	 caused	
by	 the	 increased	 levels	 of	 exon	1	HTT.	However,	 our	 data	do	not	
rule	out	 the	contribution	of	other	 factors,	 for	example,	 the	differ-
ences	between	the	mouse	and	human	polyproline	regions	of	exon	1	
present	 in	HdhQ150	and	Q140,	although	functional	consequences	




the	production	and/	or	 levels	of	 the	Httexon1	 transcript,	presents	
a	rational	approach	to	complement	existing	therapeutic	strategies.
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